ID
13423
Description
Antibiotic-associated diarrhoea (AAD) is a frequent condition in hospitalised patients receiving antibiotic treatment. The same is true for Clostridium difficile-associated diarrhoea (CDAD) with even more grave consequences of increased morbidity and mortality. The development and evaluation of preventive strategies is one key public health challenge. In the absence of clinically evaluated alternatives, probiotics have been suggested to be beneficial for the prevention of AAD and CDAD. However, data have so far been inconclusive and recently published meta-analyses strongly recommended large state-of-the-art clinical trials on probiotic substances for the prevention of AAD and CDAD. Since the efficacy, side-effects and modes of action of different probiotic bacteria and yeast are strain specific, benefits and risks cannot be generalised. The non-pathogenic yeast Saccharomyces cerevisiae var. boulardii (Sac. boulardii) is considered the most promising probiotic substance for the prevention of AAD and CDAD. We carry out a randomised, placebo controlled, double blind multicentre clinical trial to evaluate Sac. boulardii for the indication of prevention of AAD and CDAD in 1520 adult, hospitalised patients.
Keywords
Versions (3)
- 2/4/16 2/4/16 -
- 2/11/16 2/11/16 -
- 2/11/16 2/11/16 -
Uploaded on
February 11, 2016
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
SacBo TI: Case Report Form Phone Interview Medication Obligatory For Documentation DRKS00000084 NCT01143272
SacBo TI: Case Report Form Phone Interview Medication Obligatory For Documentation NCT01143272
Description
Treatment with drugs/opiates causing constipation
Description
line
Data type
integer
Description
medication name
Data type
text
Alias
- UMLS CUI [1]
- C2360065
Description
first dose
Data type
date
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0011008
Description
Date of first dose unknown
Data type
boolean
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0439673
- UMLS CUI [1,4]
- C0011008
Description
Date of last dose
Data type
date
Alias
- UMLS CUI [1]
- C1762893
Description
Date of last dose unknown
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1762893
- UMLS CUI [1,2]
- C0439673
Description
Treatment with systemic antifungal agents; note that the use of systemic antifungal agents makes the patient retrospectively ineligible for this study as of exclusion criterion 06; please record early study termination if this is the case
Description
Line
Data type
integer
Description
medication name
Data type
text
Alias
- UMLS CUI [1]
- C2360065
Description
first dose
Data type
date
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0011008
Description
Date of first dose unknown
Data type
boolean
Alias
- UMLS CUI [1,1]
- C3174092
- UMLS CUI [1,2]
- C0205435
- UMLS CUI [1,3]
- C0439673
- UMLS CUI [1,4]
- C0011008
Description
Date of last dose
Data type
date
Alias
- UMLS CUI [1]
- C1762893
Description
Date of last dose unknown
Data type
boolean
Alias
- UMLS CUI [1,1]
- C1762893
- UMLS CUI [1,2]
- C0439673
Similar models
SacBo TI: Case Report Form Phone Interview Medication Obligatory For Documentation NCT01143272
C1515021 (UMLS CUI [1,2])
C0205435 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0003232 (UMLS CUI [1,2])
C0205435 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0205435 (UMLS CUI [1,2])
C0439673 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,4])
C0439673 (UMLS CUI [1,2])
C0205435 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
C0205435 (UMLS CUI [1,2])
C0439673 (UMLS CUI [1,3])
C0011008 (UMLS CUI [1,4])
C0439673 (UMLS CUI [1,2])
No comments